Pharmaceutical

Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics’s CTX-112?

CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell Lymphoma.

Jul 2, 2024 - 04:00
CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell Lymphoma.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07...

Next Article

Risk adjusted net present value: What is the current valuation of Pfizer’s Influ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Exscientia acquires oral CDK7 inhibitor for $20m, plans breast cancer trial

Exscientia acquires oral CDK7 inhibitor for $20m, plans...

Jul 20, 2024

Opinion: Medicare has different standards than the FDA. That’s how it should be

Opinion: Medicare has different standards than the FDA....

Feb 3, 2024

Babies born to opioid users have shorter hospital stays with parental involvement: study

Babies born to opioid users have shorter hospital stays...

May 1, 2023